Compare BAP & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAP | UTHR |
|---|---|---|
| Founded | 1889 | 1996 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.4B | 23.9B |
| IPO Year | 1997 | 1999 |
| Metric | BAP | UTHR |
|---|---|---|
| Price | $320.57 | $523.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $291.60 | ★ $531.79 |
| AVG Volume (30 Days) | 355.7K | ★ 497.9K |
| Earning Date | 02-12-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | N/A | ★ 13.07 |
| EPS | N/A | ★ 27.86 |
| Revenue | N/A | ★ $1,483,300,000.00 |
| Revenue This Year | $22.58 | $7.05 |
| Revenue Next Year | $8.84 | $13.30 |
| P/E Ratio | ★ $12.91 | $18.93 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $165.51 | $266.98 |
| 52 Week High | $380.20 | $548.12 |
| Indicator | BAP | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 56.10 |
| Support Level | $319.35 | $464.92 |
| Resistance Level | $360.83 | $542.66 |
| Average True Range (ATR) | 11.40 | 13.44 |
| MACD | -1.91 | 0.51 |
| Stochastic Oscillator | 21.14 | 70.23 |
Credicorp Ltd is a Peruvian financial services company. It operates in four business lines, including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital. Geographically, the company operates in Peru, Colombia, Bolivia, Chile, Panama, the USA, and Mexico; the majority of its revenue is generated from Peru.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.